InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe
April 7, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company’s DIMS platform has been granted by the European Patent Office.InDex has a preclinical portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new European patent, entitled Biologically active oligonucleotides capable of modulating the immune system (patent number 3165607), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the